Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata

Brain Research

Volumn 777, Issue 1-2, 1997, Pages 51-59

  Özer, Hülya ^a   Ekinci, Ahmet C ^a   Starr, Michael S ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Catalepsy; Corpus striatum; Dopamine; N Methyl D aspartate receptor; Substantia nigra

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RACLOPRIDE; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR BLOCKING AGENT; SALICYLAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG EFFECT; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR CONTROL; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; ANIMAL; BRAIN LEVEL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; MALE; MICROINJECTION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BRAIN CHEMISTRY; CATALEPSY; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICROINJECTIONS; NUCLEUS ACCUMBENS; RACLOPRIDE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SALICYLAMIDES; SUBSTANTIA NIGRA;

EID: 0031589607     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00706-3     Document Type: Article

References (52)

1. [1] R.L. Albin, J.W. Aldridge, A.B. Young, S. Gilman, Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity, Brain Res. 491 (1989) 185-188.
2. [2] R.L. Albin, A.B. Young, J.B. Penney, The functional anatomy of basal ganglia disorders, Trends Neurosci. 12 (1989) 366-375.
3. [3] H. Bergman, T. Wichmann, M.R. DeLong, Reversal of experimental parkinsonism by lesions of the subthalamic nucleus, Science 249 (1990) 1436-1438.
4. [4] M.D. Bevan, A.D. Smith, J.P. Bolam, The substantia nigra as a site of synaptic integration of functionally diverse information arising from the ventral pallidum and globus pallidus in the rat, Neuroscience 75 (1996) 5-12.
5. [5] F. Blandini, J.T. Greenamyre, G. Nappi, The role of glutamate in the pathophysiology of Parkinson's disease, Funct. Neurol. 11 (1996) 3-15.
6. [6] A.V. Christensen, J. Arnt, J. Hyttel, J.-J. Larsen, O. Svendsen, Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics, Life Sci. 34 (1984) 1529-1540.
7. [7] B. Costall, R.J. Naylor, J.E. Olley, Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain, Neuropharmacology 11 (1972) 645-652.
8. [8] W. Danysz, M. Gossel, W. Zajaczkowski, D. Dill, G. Quack, Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine, J. Neural Transm. [P-D Sect.] 7 (1994) 155-166.
9. [9] B. Ellenbroek, M. Schwarz, K.-H. Sontag, R. Jaspers, A. Cools, Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats, Brain Res. 345 (1985) 132-140.
10. [10] P.J. Elliott, S.P. Close, D.M. Walsh, A.G. Hayes, A.S. Marriott, Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists, J. Neural Transm. [P-D Sect.] 2 (1990) 91-100.
11. [11] G.H. Fletcher, M.S. Starr, Intracerebral SCH 23390 and catalepsy in the rat, Eur. J. Pharmacol. 149 (1988) 175-178.
12. [12] C.R. Gerfen, The neostriatal mosaic: multiple levels of compartmental organization, Trends Neurosci. 15 (1992) 133-139.
13. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science 250 (1990) 1429-1432.
14. [14] J.T. Greenamyre, C.F. O'Brien, N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease, Arch. Neurol. 48 (1991) 977-981.
15. [15] W. Hauber, M.T. Waldenmeier, The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849, Eur. J. Pharmacol. 256 (1994) 339-342.
16. [16] T. Honma, H. Fukushima, Effects of bilateral lesions in the striatum or nucleus accumbens on the cataleptogenic activity in rats, Jpn. J. Pharmacol. 28 (1978) 231-238.
17. [17] J. Hyttel, SCH 23390 - the first selective dopamine D-1 antagonist, Eur. J. Pharmacol. 91 (1983) 153-154.
18. [18] F.G. Kaddis, L.J. Wallace, N.J. Uretsky, AMPA/kainate antagonists in the nucleus accumbens inhibit locomotor stimulatory response to cocaine and dopamine agonists, Pharmacol. Biochem. Behav. 46 (1993) 703-708.
19. [19] R. Karler, L.D. Calder, L.H. Thai, J.B. Bedingfield, A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine, Brain Res. 658 (1994) 8-14.
20. [20] S. Kaur, H. Özer, M.S. Starr, MK-801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain, Eur. J. Pharmacol., submitted.
21. [21] S. Kaur, M.S. Starr, Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat, Neuroscience 76 (1997) 345-354.
22. [22] A.E. Kelley, L.C. Throne, NMDA receptors mediate the behavioral effects of amphetamine infused into the nucleus accumbens, Brain Res. Bull. 29 (1992) 247-254.
23. [23] T. Klockgether, L. Turski, NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats, Ann. Neurol. 28 (1990) 539-546.
24. [24] K.B. Koffer, S. Berney, O. Hornykiewicz, The role of the corpus striatum in neuroleptic- and narcotic-induced catalepsy, Eur. J. Pharmacol. 47 (1978) 81-86.
25. [25] J. Kornhuber, M. Weller, P. Riederer, Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis, J. Neural Transm. [P-D Sect.] 6 (1993) 63-72.
26. 1 receptor mediated catalepsy in rats, J. Neural Transm. [Gen. Sect.] 95 (1994) 123-136.
27. [27] W. Löscher, R. Annies, D. Hönack, The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats, Neurosci. Lett. 128 (1991) 191-194.
28. [28] W. Löscher, R. Annies, D. Hönack, Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats, Eur. J. Pharmacol. 242 (1993) 263-274.
29. [29] P. Martin, A. Svensson, A. Carlsson, M.L. Carlsson, On the roles of dopamine D-1 vs. D-2 receptors for the hyperactivity response elicited by MK-801, J. Neural Transm. [P-D Sect.] 95 (1994) 113-121.
30. [30] A.K. Mehta, M.K. Ticku, Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats, Life Sci. 46 (1990) 37-42.
31. 2 receptor antagonists, Eur. J. Pharmacol. 237 (1993) 1-7.
32. [32] S. Narayanan, D. Willins, A. Dalia, L. Wallace, N. Uretsky, Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens, Pharmacol. Biochem. Behav. 54 (1996) 565-573.
33. 2-receptor antagonists induce catalepsy via different efferent striatal pathways, Neurosci. Lett. 85 (1988) 333-338.
34. [34] K. Ossowska, The role of excitatory amino acids in experimental models of Parkinson's disease, J. Neural Transm. [P-D Sect.] 8 (1994) 39-71.
35. 2 dopamine receptors in neuroleptic catalepsy, Eur. J. Pharmacol. 182 (1990) 327-334.
36. 2 receptor blockade on MK-801-induced hyperlocomotion in rats, Psychopharmacology 111 (1993) 427-434.
37. [37] S.M. Papa, T.M. Engber, R.C. Boldry, T.N. Chase, Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists, Eur. J. Pharmacol. 232 (1993) 247-253.
38. [38] G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1982.
39. [39] W.J. Schmidt, M. Bubser, Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats, Pharmacol. Biochem. Behav. 32 (1989) 621-623.
40. [40] D.G. Standaert, C.M. Testa, J.B. Penney, A.B. Young, Alternatively spliced isoforms of the NMDAR1 glutamate receptor; differential expression in the basal ganglia of the rat, Neurosci. Lett. 152 (1993) 161-164.
41. 2 balance in the basal ganglia and its relevance to Parkinson's disease, Synapse 19 (1995) 264-293.
42. [42] M.S. Starr, Antiparkinsonian actions of glutamate antagonists -alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms, J. Neural Transm. [P-D Sect.] 10 (1995) 141-185.
43. [43] J.-A. St-Pierre, P.J. Bédard, Intranigral but not intrastriatal micro-injection of the NMDA antagonist MK-801 induced contralateral circling in the 6-OHDA rat model, Brain Res. 660 (1994) 255-260.
44. 2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice, J. Neural Transm. 90 (1992) 199-217.
45. [45] R. Van den Bos, A.R. Cools, Involvement of the substantia innominata/ventral pallidum complex in transmitting forelimb muscular rigidity evoked from the nucleus accumbens in rats, Neurosci. Lett. 103 (1989) 303-308.
46. 2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats, Psychopharmacology 109 (1992) 477-483.
47. [47] P.S. Whitton, C.S. Biggs, B.R. Pearce, L.J. Fowler, Regional effects of MK-801 on dopamine and its metabolites studies by in vivo microdialysis, Neurosci. Lett. 142 (1992) 5-8.
48. [48] D.L. Willins, S. Narayanan, L.J. Wallace, N.J. Uretsky, The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK-801, Pharmacol. Biochem. Behav. 46 (1993) 881-887.
49. [49] B.K. Yamamoto, S. Davy, Dopaminergic modulation of glutamate release in striatum as measured by microdialysis, J. Neurochem. 58 (1992) 1736-1742.
50. [50] Y. Yoshida, T. Ono, K. Kawano, T. Miyagishi, Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen, Brain Res. 639 (1994) 139-148.
51. [51] Y. Yoshida, T. Ono, A. Kizu, R. Fukushima, T. Miyagishi, Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy, Eur. J. Pharmacol. 203 (1991) 173-180.
52. [52] J. Zhang, L.A. Chiodo, A.S. Freeman, Electrophysiological effects of MK- 801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons, Brain Res. 590 (1992) 153-163.